Clients and Partners
“At Radiopharm Theranostics, we’re driven by the goal of bringing transformative radiopharmaceutical therapies to patients who need them most. Partnering with AtomVie has ...” Read more
“Cellectar and AtomVie (CPDC at the time) have been working together since 2016 to manufacture CLR-131 and bring this compound to market. Through ...” Read more
“AtomVie, and CPDC before it, has been a great partner to POINT. Their support in the submission of our Canadian Clinical Trial applications ...” Read more
“At Radiopharm Theranostics, we’re driven by the goal of bringing transformative radiopharmaceutical therapies to patients who need them most. Partnering with AtomVie has been an outstanding experience, allowing us to take several steps forward to achieve our mission. AtomVie's deep expertise in radiopharmaceutical manufacturing, commitment to quality, and collaborative approach have made them a trusted partner as we advance our clinical programs. AtomVie operates with the responsiveness and scientific rigor we value, and we’re proud to work alongside a team that shares our dedication to innovation and patient impact.”
“Cellectar and AtomVie (CPDC at the time) have been working together since 2016 to manufacture CLR-131 and bring this compound to market. Through their successful track record, AtomVie has proven that they are an excellent manufacturing solution for us to take on a long-term and sustainable journey. AtomVie with their diligence, commitment, and unique expertise working with I-131, has made us confident in their abilities to assist us in supplying and commercializing CLR-131.”
“AtomVie, and CPDC before it, has been a great partner to POINT. Their support in the submission of our Canadian Clinical Trial applications for our radioligand programs has been instrumental in accelerating our pipeline of next generation radioligand therapies.”